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Abstract Remote Ischemic Preconditioning (RIPC) is a non-
invasive cardioprotective intervention that involves brief cy-
cles of limb ischemia and reperfusion. This is typically deliv-
ered by inflating and deflating a blood pressure cuff on one or
more limb(s) for several cycles, each inflation-deflation being
3–5 min in duration. RIPC has shown potential for protecting
the heart and other organs from injury due to lethal ischemia
and reperfusion injury, in a variety of clinical settings. The
mechanisms underlying RIPC are under intense investigation
but are just beginning to be deciphered. Emerging evidence
suggests that RIPC has the potential to improve exercise per-
formance, via both local and remote mechanisms. This review
discusses the clinical studies that have investigated the role of
RIPC in cardioprotection as well as those studying its appli-
cability in improving athletic performance, while examining
the potential mechanisms involved.
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Introduction
Ischaemic preconditioning (IPC) is a phenomenon in which
transient episodes of ischemia and reperfusion administered to
an organ attenuate the lethal cellular injury sustained from a
subsequent, prolonged ischaemic insult of the same organ.
IPC was first described in a study by Murray et al. in 1986
[1], in which, the hearts of anaesthetized dogs were
preconditioned with four 5 min occlusions of the circumflex
artery, each separated by 5 min of reperfusion. This was
followed by a sustained 40 min occlusion and 4 days of reper-
fusion. The extent of myocardial infarction in the
preconditioned hearts was found to be dramatically reduced
to a mere 25 % of that seen in the control hearts which did not
receive preconditioning [1]. Later, IPC was also shown to
have the ability to prevent lethal ischemia and reperfu-
sion injury in skeletal muscles, and to protect the endo-
thelium [2, 3].
Subsequently, the intriguing observation was made that
protection of the heart could also be achieved by applying
cycles of brief ischemia, alternating with reperfusion, to a
tissue or organ remote from the heart - a concept named re-
mote ischaemic preconditioning (RIPC). A crucial intermedi-
ate step towards the discovery of RIPC was made by
Przyklenk et al. [4] in 1993, who demonstrated that precondi-
tioning the territory of the heart supplied by the circumflex
coronary artery also reduced the size of the infarct arising from
the subsequent occlusion of the left anterior descending coro-
nary artery. They called this phenomenon “preconditioning at
a distance” [4]. This was followed by studies showing that
preconditioning of the heart could be achieved by applying
the brief episodes of ischemia and reperfusion to a remote
organ such as the kidney or other abdominal visceral organs
[5, 6]. Birnbaum et al. made the critical observation that RIPC
could also be applied to the limb. In their experiments, they
combined brief cycles of blood flow restriction with electrical
stimulation of the gastrocnemius muscle in the same limb in
order to induce demand ischemia [7]. When applied prior to
sustained coronary artery occlusion and reperfusion, this in-
tervention reduced infarct size by more than 65 % [7].
Kharbanda et al. were the first to demonstrate that the appli-
cation of an RIPC stimulus without the need for electrical
stimulation, reduced the extent of myocardial infarction in-
vivo in pigs, and also attenuated endothelial injury in humans
[8]. This study paved the way for the clinical application of
RIPC by recognising the possibility of a non-invasive method
of protecting the heart against lethal IR injury. Other studies
demonstrated that in addition to protecting the heart, limb
RIPC can also protect other organs including the kidneys,
lungs, brain, and liver [9], as well as the endothelium [10]
from injury caused by sustained ischemia and reperfusion.
In addition to the benefits of IPC and RIPC on the heart and
the endothelium, both in terms of increased resistance to isch-
aemic injury and preservation of function in the face of ische-
mia and reperfusion, it has been hypothesised that IPC applied
to the limb may have the potential to improve exercise perfor-
mance via both local effects (i.e.,: to the limb) and remote
effects (via the cardiovascular or nervous system). We refer
to this approach here as “limb IPC” to distinguish it from the
concept of using RIPC to target the remote organ alone. This
review will appraise and discuss the studies that have evalu-
ated the role of RIPC in preventing myocardial IR injury, as
well as discussing the potential local and remote effects of
limb IPC in improving exercise performance.
Protecting the Heart with Remote Ischaemic
Preconditioning
Clinical Applications
RIPC has been shown to be a promising technique for reduc-
ing ischaemic myocardial cell death in various animal studies
[4–8]. Although the procedure has been successfully applied
following myocardial infarction in proof-of concept clinical
trials [11–16], its clinical application is more conveniently
studied in settings in which a sustained ischaemic insult can
be predicted, which allows it to be administered prior to the
ischemic insult. For example, some elevation of cardiac en-
zymes typically occurs peri-operatively in patients undergoing
coronary artery bypass grafting [17]. Myocardial infarction
occurring in this setting is termed “type 5” myocardial infarc-
tion [17]. Cardiac surgery therefore is a controlled clinical
setting amenable to the investigation of the cardioprotective
effects RIPC (Table 1).
Cheung et al. [18] were the first to successfully use RIPC in
patients undergoing cardiac surgery, in a study assessing the
effects of RIPC on children undergoing surgery to repair
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congenital heart defects. RIPC was induced by four 5 min
cycles of lower-limb ischemia and reperfusion by inflation
of a blood pressure (BP) cuff to 15 mmHg above the resting
systolic arterial pressure (measured invasively via an arterial
line), and compared against a control group who received no
RIPC. They uncovered multiple positive effects of RIPC ad-
ministered prior to surgery. Postoperative levels of troponin I
and postoperative inotropic requirement were reduced in the
RIPC group indicating less myocardial injury and better re-
covery of contractile function. In addition, the RIPC group
had significantly lower airway resistance postoperatively.
The effects of RIPC on patients undergoing coronary artery
bypass surgery (CABG) have been widely explored since, but
with inconsistent findings [18–27]. Table 1 lists studies ex-
ploring the ability of RIPC given prior to CABG to mitigate
myocardial injury (measured by rise in cardiac enzymes post
operatively) and improve clinical outcomes post CABG sur-
gery. Results have been mixed, with some demonstrating that
RIPC is beneficial, reducing the extent of cardiac enzyme
release, and others reporting no additional benefit over stan-
dard therapies (Table 1). An important caveat with these stud-
ies is that it is unclear to what extent the reduction of cardiac
enzymes post operatively can be expected to translate to an
improvement in clinical outcomes.
Another limitation in the clinical application of RIPC is the
lack of a standardized optimal protocol for delivery of the
RIPC stimulus in humans. The currently used protocols have
been extrapolated from animal studies and there is a lack of
evidence to guide what dose of RIPC is sufficient to trigger a
cardioprotective response. We have recently shown that the
magnitude of ischemia that occurs in the limb during RIPC
differs widely based on the limb (upper vs. lower) and the cuff
inflation pressure used [28], suggesting a need for more re-
search to standardise the RIPC protocol, so that it can be
delivered in a consistent manner in humans. Table 1 empha-
sizes the broad variations in RIPC protocols that have been
applied in clinical trials. Differences include: the number of
cycles of RIPC (typically two to four), length of the cycles (3
to 5 min), the choice of limb(s) used to deliver RIPC, and cuff
inflation pressure which may be either a predetermined pres-
sure or a pre-defined level above the resting systolic blood
pressure. These differences may account for some of the var-
iation in results noted with RIPC in the setting of CABG. An
additional factor that may influence the results of these clinical
trials is the choice and timing of anaesthetic agents used dur-
ing surgery, since it is known that certain volatile anaesthetic
agents can themselves precondition the heart against ischemic
insults [29].
Other confounding factors may interfere with RIPC in pa-
tients undergoing CABG, including age, co-morbidities and
other medications that the patients are taking peri-operatively.
In addition, the mechanisms of myocardial injury and cardiac
Table 1 Clinical trials exploring benefits of RIPC in patients undergoing coronary artery bypass grafting (I=Ischemia, R=reperfusion)
Study Number
of patients
RIPC stimulus: limb(s) used, duration of I-R (min),
number of RIPC cycles, cuff inflation pressure
Outcome
Cheung et al. [18] 37 Lower limb
5′ I 5′ R (x4); 15 mmHg above systolic arterial BP
Reduced cTnT release,
Reduced inotrope requirement after surgery,
Reduced airway resistance
Venugopal et al. [26] 45 Upper limb 5′ I 5′ R (x3); 200 mmHg Reduced absolute cTnT release post surgery
Hausenloy et al. [22] 57 Upper limb
5′ I 5′ R (x3); 200 mmHg
Reduced cTnT release postoperatively
Thielmann et al. [25] 53 Upper limb
5′ I 5′ R (x3); 200 mmHg
Reduced cTnI release postoperatively
Gunaydin et al. [21] 8 Lower limb
3′ I 2′ R (x2); 200 mmHg
No change in CK-MB
Rahman et al. [24] 162 Upper limb
5′ I 5′ R (x3); 200 mmHg
Troponin-T release unaffected by RIPC
Wagner et al. [27] 101 Upper limb
5′ I 5′ R (x3); 40 mm Hg above resting systolic
BP- given 18 h prior to surgery
Reduced cTnI release post-operatively
Kottenberg et al. [23] 72 Upper limb
5′ I 5′ R (x3); 200 mmHg
RIPC during isoflurane anaesthesia reduces post-op
cTnI release, but not during Propofol anesthesia
Candilio et al. [19] 180 One upper and one lower limb simultaneously
5′I 5′R (x2); 200 mm Hg or to 15 mmHg
above systolic BP if systolic BP >185 mmHg
Reduced perioperative TnI release, reduced incidence
of post-op AF/AKI and duration of ICU stay
Gedik et al. [20] 20 Upper limb
5′ I 5′ R (x3)
Reduced TnI release post-operatively
Hausenloy et al. [30] 1,610 Upper limb
5′ I 5′ R (x4);
200 mm Hg
No significant difference in 30 day MACCE or
1 year clinical outcomes
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enzyme elevation in this setting are fairly diverse, and include
type 2 myocardial infarction, macrovascular events such as
graft failure, injury to the myocardium from surgical manipu-
lation, microvascular injury and release of a cytosolic pool of
cardiac enzymes without necrosis [17]. These factors result in
only a very small target potentially amenable to protection that
may be overwhelmed by the contribution from other sources
of cardiac injury, making the benefits of RIPC in this setting
more difficult to ascertain.
A further hurdle is the current paucity of data regarding the
optimal time window of protection from RIPC and the dura-
tion of its effect. The duration of CABG surgery itself can vary
significantly making it difficult to accurately time RIPC inter-
vention prior to CABG. Finally, the myocardium is already
protected during CABG by the use of standard cardioplegia
techniques, which themselves are extremely effective in min-
imizing ischemic insult to the myocardium.
Considering these challenges, it is perhaps not entirely sur-
prising that the first large, double-blinded, randomized, multi-
centre study of RIPC in 1,610 patients undergoing CABG (the
ERICCA trial) [30], did not show a significant clinical improve-
ment using a primary combined endpoint of cardiovascular
death, non-fatal myocardial infarction, coronary revasculariza-
tion and stroke after 1 year (results presented at ACC 64th an-
nual scientific meeting) [30]. More unexpectedly, however,
RIPC did not significantly reduce the release of biomarkers of
cardiac injury. One interpretation of these results is that CABG
may not, in fact, be the ideal experimental setting for application
of RIPC, particularly in view of the factors mentioned above.
Importantly, in a multicentre, single-blinded, randomized
controlled trial of 519 patients experiencing ST-segment ele-
vation myocardial infarction who were administered throm-
bolysis in the developing nation of Mauritius, significantly
less release of cardiac enzymes was measured in those who
received RIPC [16]. This inspires confidence that, in a setting
where the degree of cardiac injury due to the ischaemia and
reperfusion injury is more marked, the benefit of RIPC can be
clearly observed.
The cardio-protective effects of RIPC are also being ex-
plored in other clinical settings, such as in patients undergoing
elective percutaneous coronary intervention (PCI). In this sce-
nario, myocardial injury can be anticipated [17], but contrast-
induced acute kidney injury (nephropathy) may also occur,
and has been proposed as an additional target for protection
by RIPC. The results of trials evaluating the benefits of RIPC
in elective PCI are fairly mixed (Table 2), in terms of both the
effect of RIPC on peri-procedural myocardial infarction and
clinical outcomes following PCI [31–40].
RIPC has also been evaluated for its ability to protect the
myocardium and improve clinical outcomes in patients pre-
senting with an acute myocardial infarction (both NSTEMI
and STEMI) who undergo PCI [11–16]. Since the myocardi-
um is already ischaemic in these patients when they present
with an evolving infarction, RIPC protocols in this setting are
referred to as “per-conditioning” (RIPercon) when RIPC is
given prior to PCI, and as “post-conditioning” (RIPostC)
when given during or after PCI. Results are more promising
in this setting and demonstrate that RIPercon or RIPostC can
reduce myocardial injury and acute kidney injury related to
PCI as well as improve long-term clinical outcomes in patients
undergoing PCI for acute myocardial infarction, in terms of
MACCE comprising of a composite of all-cause mortality,
myocardial infarction, readmission for heart failure, and ische-
mic stroke/transient ischemic attack [14]. Interestingly, met-
analyses of trials in patients undergoing both elective and
emergent PCI (for acute myocardial infarction) have shown
a benefit for RIPC in terms of both myocardial and kidney
injury, although data from large-scale, randomized clinical
trials is still missing [41–45]. Despite the more consistent
benefit observed in this setting, a wide range of protocols have
been utilized to evaluate the role of RIPC in PCI (Table 2) –
which vary in the number of cycles of RIPC [1–4], the dura-
tion of cuff inflation/deflation (1–5 min), the cuff inflation
pressure used (200 mmHg or 50 mmHg above resting blood
pressure), choice of limbs(s) used for RIPC and the timing of
RIPC with regards to the PCI or the ischemic insult (i.e.
RIPercon or RIPostC). As with CABG, additional factors
can potentially influence the effects of RIPC, including pa-
tients’ comorbidities, co-medications, as well as some of the
agents typically used to reducemyocardial injury in the setting
of acute MI such as heparin, antiplatelet agents, statins, and
anti-coagulants - all of which may mask or minimize the po-
tential additional benefit of RIPC.
Larger trials are currently underway including the ERIC-
pPCI trial (evaluating RIPC in the setting of pPCI for STEMI)
and the EURO-CRIPS trial [46] (evaluating RIPC in the set-
ting of PCI being performed for all indications apart from
STEMI), which will help to clarify if RIPC truly has a bene-
ficial impact on clinical outcomes in patients undergoing PCI.
Yet another field in which RIPC may be effective, is in
preventing perioperative ischaemic myocardial injury in heart
transplantation surgery [47]. Konstantinov et al. showed that
in pigs, RIPC of the recipient animal could reduce ischemia-
reperfusion injury sustained by the donor heart after
orthotopic transplantation [48]. In their study, four 5-min cy-
cles of lower limb ischemia and reperfusion in the recipient
animals served as the RIPC stimulus and the left anterior de-
scending artery of the transplanted heart was occluded for
30 min following heart transplantation to test whether there
was protection against ischemia and reperfusion injury [48].
Remotely preconditioned recipient pigs sustained myo-
cardial infarctions in the transplanted hearts that were
63 % smaller than control pigs. Another interesting conclu-
sion that may be made from this experiment is that neural
innervation to the heart is not essential for delivery of the
cardioprotective stimulus.
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Interestingly, RIPC has also been shown to be effective in
preventing myocardial injury even in the setting of non-
cardiac surgery such as abdominal aortic aneurysm repair.
Ali et al. determined that RIPC could reduce myocardial inju-
ry as well as renal injury in patients undergoing open abdom-
inal aortic aneurysm repair [49]. RIPC was achieved using
two cycles of occlusion of the common iliac artery with
10 min ischemia followed by 10 min reperfusion. RIPC re-
duced the incidence of myocardial injury and myocardial in-
farction by 27 and 22 % respectively (assessed by measure-
ment of perioperative release of Troponin I [49]. The mecha-
nism of myocardial injury in this setting is unclear.
Thus RIPC has shown a potential for being able to protect
the heart against lethal ischemia reperfusion in a wide range of
clinical settings, though proof of its utility in improving clin-
ical outcomes in these settings from large randomised con-
trolled clinical trials is still awaited. There are several hurdles
in its clinical implementation, discussed above, which have so
far prevented RIPC from being applied on a routine basis in
clinical practice. This could change in the future as we under-
stand better the limitations in its application as well the mech-
anisms that underlie this cardioprotective phenomenon.
Mechanisms Underlying RIPC Mediated Protection
of the Heart
Innate Protective Pathways within the Myocardium Activated
by RIPC
The mechanisms within the heart that lead to cardioprotection
from RIPC are similar to those involved in direct IPC of the
heart [50]. IPC itself appears to begin with ligand binding to
G-protein coupled receptors on the surface of the
cardiomyocytes. These ligands include adenosine, bradykinin,
opioids, angiotensin and endocannabinoids. The binding of
cardiomyocyte surface receptors to the respective ligands ini-
tiates signalling pathways, which eventually lead to changes
in the myocardium, rendering it resistant to ischaemia and
reperfusion injury [50, 51]. One of the important innate
cardioprotective pathways activated via IPC is the Reperfu-
sion Injury Salvage Kinase (RISK) pathway [50].
Cardioprotection from RIPC has, similarly, been shown to
be associated with phosphatidylinositol-3-OH kinase
(PI3K)-Akt activation, which is an integral component of the
RISK pathway [52], suggesting similar mechanisms underly-
ing IPC and RIPC.
Activation of the RISK pathway is known to inhibit the
mitochondrial permeability transition pore (mPTP), which ap-
pears to be the final target of this cardioprotective pathway
[53]. Opening of the mitochondrial permeability transition
pore (mPTP) during reperfusion results in both necrotic cell
death, due to ATP depletion, and apoptotic cell death, due to
swelling and rupture of mitochondria [54]. Though, it is clearTa
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how preventing the opening of mPTP by IPC provides
cardioprotection, direct evidence linking RIPC to inhibition
of mPTP opening has yet to be obtained. RIPC-induced pro-
tection from reperfusion injury has also been shown to be
mediated by the activation of Signal Transducer and Activator
of Transcription (STAT)-3 proteins which act through a differ-
ent cardioprotective pathway, called the survivor activating
factor enhancement (SAFE) pathway [55]. There are many
proposedmechanisms to explain how the SAFE pathway con-
fers protection to the myocytes [56], with evidence that the
mPTP may again be the key end effector [57]. The RISK and
SAFE pathways are not mutually exclusive and there is evi-
dence of interaction between them [55].
There is much evidence to suggest that another pathway
involving ATP-sensitive potassium (KATP) channels play a
role in cardioprotection offered by IPC. In particular mito-
chondrial KATP channels have been implicated in this protec-
tion, with Garlid et al. [58] and Liu et al. [59] demonstrating
that KATP opener diazoxide mimicked the cardioprotective
effects of IPC and was a far more potent opener of mitochon-
drial KATP than sarcolemmal KATP. Similar to its role in medi-
ating protective effects of IPC, KATP channels have been im-
plicated in cardioprotective effects of RIPC, working indepen-
dently of the neural pathways of RIPC protection [48]. There
are several theories that attempt to explain how the opening of
KATP channels could lead to cardioprotection. Costa et al.
demonstrated that opening of KATP channels inhibits the open-
ing of the mitochondrial permeability transition pore (mPTP),
similar to the RISK and SAFE pathways, leading to
cardioprotection [60]. Opening of KATP channels appears to
lead to the activation of downstream protein kinases like Pro-
tein kinase C (PKC), via generation of reactive oxygen species
during reperfusion. These downstream kinases (in particular
the PKC-ε isoform) then relay the cardioprotective signal to
the end-effectors of cardioprotection leading to the inhibition
of the opening of mPTP [61]. Protein kinase C (PKC) has
additionally been shown to play a critical role as a mediator
of the preconditioning signal in IPC with many studies dem-
onstrating the role of the PKC-ε isoform in cardioprotection
from IPC [61–63]. Likewise, studies have linked PKC-ε acti-
vation with RIPC by showing that the cardioprotective effects
of RIPC can be abolished by PKC blocker chelerythrine [64].
The intracellular targets of PKC have yet to be established,
however.
Mechanisms Involved in Transmission of RIPC Signal
to the Heart
Intriguingly, though the protective changes within the myo-
cardium that take place secondary to RIPC are well studied (as
reviewed above), the means by which the protective stimulus
is communicated to the heart from the remote tissue on which
RIPC is performed remains unclear. The two primary theories
for mechanistic pathways linking the remote tissue to the heart
involve either the release of a humoral factor in the remote
tissue that is transported to the heart or a protective signal
transmitted through a neural pathway between the remote tis-
sue and the heart (Fig. 1) [65]. These pathways are not mutu-
ally exclusive and it is likely they interact with each other to
facilitate RIPC. This idea is supported by a recent study, which
found that the cardioprotective effect of RIPC was partially
blocked by either femoral vein occlusion (humoral pathway)
or sciatic nerve resection (neural pathway) but completely
abolished by a combination of the two [65]. This also suggests
that both mechanisms may (at least partially) transmit the
cardioprotective signal independently to the heart.
Humoral Pathway of Transmission of RIPC Signal to the
Heart There have been many experimental studies, which
support the idea that a humoral factor released at the remote
tissue plays a role in RIPC. Studies have shown that rabbits
which received either whole blood transfusion or coronary
effluent transfusion from donor rabbits that had undergone
ischaemic preconditioning are as well protected frommyocar-
dial infarction as donor preconditioned rabbits [66]. The fact
that this protection was successfully transferred from
preconditioned rabbits to untreated rabbits via blood transfu-
sion supports the idea that a humoral factor conveys the pre-
conditioning signal from the remote organ to the heart. This
theory is also reinforced by the previously mentioned study by
Konstantinov et al., which showed that RIPC of the recipient
could reduce myocardial infarction sustained by the denervat-
ed donor heart. This implies that protection can be transferred
through the blood, independent of the neural pathway [48].
Evidence that a humoral factor is involved in RIPC may be
strong, but the identity of such factors is still under investiga-
tion. A study by Serejo et al. using coronary effluent transfu-
sion from preconditioned mice to untreated mice demonstrat-
ed that the cardioprotective factor released by IPC is thermo-
labile, hydrophobic substance with a molecular weight greater
than 3.5 kDa [67]. A subsequent study by Shimizu et al. dem-
onstrated that the cardioprotective factor had a molecular
weight less than 15 kDa [68]. A recent study from our own
lab found that plasma levels of stromal cell-derived factor-1
(SDF-1α), a chemokine of ~10 kDa size, is significantly in-
creased in rat plasma following RIPC, and that AMD3100, a
highly specific inhibitor of SDF-1α receptor CXCR4, blocked
the cardioprotection afforded by RIPC [69]. Intriguingly, this
chemokine falls in the size range described for the humoral
factor involved in RIPC in other studies cited earlier. Another
humoral factor implicated in RIPC is Calcitonin gene-related
peptide (CGRP) and this factor appears to work via activation
of PKC-ε in the myocardium after a RIPC stimulus [70].
However, disappointingly, in an extensive human proteomic
analysis by Helgeland et al., no plasma protein could be con-
clusively demonstrated to be regulated via RIPC, although
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they recognized that this method has limited sensitivity in the
range of low to medium abundance proteins [71]. They sug-
gested that further research should focus on smaller humoral
factors, which may work in conjunction to transmit the pro-
tective signal of RIPC. Interestingly, we have recently shown
that exosomes, which are cell-derived vesicles 30–100 nm in
size, can transmit a cardioprotective signal via the blood [72].
Exosomes and similar extracellular vesicles carry a number of
signalling agents, such asmicro-RNAs (miRNAs), which play
a regulatory role in a number of intracellular pathways and
may have a role to play in RIPC, though this has yet not been
established [73–75]. miRNAs themselves (in particular
miRNA-144 and miRNA-1) have also been implicated in
RIPC mediated protection [40, 76, 77].
A number of studies have demonstrated that the protection
offered by RIPC to the heart and other organs can be abolished
using inhibitors of various opioid and cannabinoid receptors
[78–83]. This suggests that endogenous opioids and cannabi-
noids may be released at the remote organ during RIPC and
carried to the heart in the blood where they act directly on
receptors in the myocardium or other organs being targeted
via RIPC, although it is also possible that they are released
locally, in the heart. Furthermore, there is evidence for the
involvement of angiotensin-1 receptors and hypoxia inducible
factor-prolyl 4-hydoxylases in cardioprotection induced
through RIPC via occlusion of the renal artery [84, 85].
In summary, despite a number of studies showing a role of
various humoral factors in the transmission of the protective
effects of RIPC from a remote organ to the heart, no single
factor has to date been conclusively identified as the mediator
of this protection. Identification of such as factor would great-
ly aid clinical implementation of RIPC, as it would enable
optimization of RIPC protocols and optimal timing for this
intervention to achieve the maximum cardioprotection by
RIPC.
Neural Pathway of Transmission of RIPC Signal to the
HeartWhile numerous studies that have explored the humor-
al pathways of RIPC protection, others have likewise shown a
crucial role of a neural pathway of protection underlying RIPC
[86, 87]. In one of the first studies of RIPC, Gho et al. showed
that ganglion blockade by hexamethonium eliminated the
cardioprotection induced by RIPC [6]. A study by Liem
et al. showed that RIPC led to local release of adenosine that
activated a neural pathway, which subsequently leads to acti-
vation of myocardial adenosine receptors, implicating a role
for adenosine in the neural pathway of RIPC protection [88].
A study by Ding et al. also demonstrated that adenosine re-
leased in the remote organ undergoing ischemia-reperfusion,
to induce RIPC, stimulates afferent nerve signals that confer
cardioprotection [89], similar to the study by Liem et al.
Interestingly, the first evidence for the involvement of
adenosine in RIPC was obtained in 1998, when Pell et al.
demonstrated that the administration of the non-selective
adenosine receptor antagonist 8-sulfophenyltheophylline be-
fore RIPC at the renal artery abolished its cardioprotective
effects [90]. This finding was supported by Takaoka et al.,
who found that 8-sulfophenyltheophylline administration af-
ter the RIPC protocol had the same effect. They also discov-
ered that plasma levels of adenosine in carotid artery blood
were higher in rabbits subjected to RIPC (delivered via renal
artery occlusion), compared to rabbits subjected to IPC within
the heart itself, providing further evidence that adenosine is
involved in signalling between the remote tissue and heart in
Fig. 1 Schematic diagram of the
mechanisms involved in the local
and remote (cardioprotective)
effects of limb IPC
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RIPC [91]. Evidence that adenosine plays an important role in
the neural pathway of RIPC protection was later provided in
the aforementioned studies by Liem et al. [88] and Ding
et al.[89]. Dong et al. provided more evidence supporting a
neural pathway mediated by adenosine in RIPC by demon-
strating that intrafemoral artery injection of adenosine pro-
duced similar cardioprotective effects to those of RIPC deliv-
ered via femoral artery occlusion, and that femoral nerve sec-
tion abolished the effects of the RIPC [92]. Much of the ex-
perimental evidence therefore suggests that RIPC generates
adenosine in the remote tissue, which then activates afferent
sensory nerves. However, it is also possible that adenosine
also acts as a humoral factor, binding directly to receptors
within the myocardium. There is some evidence showing that
other signalling molecules such as bradykinin may also play a
role in the neural pathway of RIPC induced protection [64,
93]. Mastitskaya et al. have demonstrated a crucial role of
preganglionic vagal neurones located in the brainstem dorsal
motor nucleus of the vagus nerve in the cardioprotection of-
fered by RIPC, suggesting the neural pathway may be central-
ly integrated and regulated [87].
In conclusion, numerous triggers, mediators and effectors
of RIPC have been investigated leading to considerable prog-
ress towards our understanding how the effects of RIPC on the
heart may be mediated. The current evidence seems to support
the idea that many pathways and physiological systems are
affected acutely by RIPC, suggesting that cardioprotection
may not be the only outcome of using this intervention.
Improving Exercise Performance with Limb IPC
The demonstration of the favourable effects of IPC and RIPC
on endothelial function, skeletal muscle and the heart raised
the possibility that, in addition to being of benefit in a clinical
setting, limb IPC could also be applicable in sport. Intense
exercise has been shown to lead to cardiac and skeletal muscle
hypoxemia and may therefore represent a form of ischaemic
insult [94]. A number of recent studies have investigated
whether IPC applied to the limb prior to exercise can improve
exercise performance (Table 3), via local effects on the limb/s
and/or via mechanisms acting remotely on other organs, par-
ticularly the heart. The evidence for limb IPC improving ex-
ercise performance and the proposed mechanisms behind it
will be examined in this section.
In 2009, De Groot et al. hypothesised that limb IPC would
improve exercise performance and maximal oxygen con-
sumption [95]. In their study of well-trained cyclists they
found that preconditioning by three 5 min cycles of ischemia
and reperfusion in both legs using blood pressure cuffs inflat-
ed to 220 mmHg significantly increased maximal oxygen up-
take and power output in healthy subjects exercising on a
bicycle ergometers [95]. The authors speculated that
enhancement of skeletal muscle vasodilation could have ex-
plained the improvements in performance. Limb IPC may
achieve these effects through the activation of vascular
smooth muscle KATP channels and local release of adenosine,
which can both contribute to vasodilation in muscles [96, 97]
during exercise. Both the activation of KATP channels and the
local release of adenosine have also been implicated as medi-
ators of the effects of RIPC, as previously outlined. Previous
studies have shown that limb IPC can additionally protect the
endothelium from ischemia-reperfusion injury both locally
and remotely, preserving endothelial function in the wake of
ischemia [10, 98] and these effects might improve exercise
performance by maintaining the supply of oxygen and energy
substrates to the skeletal muscles during intense exercise,
when the exercising muscle groups might be subject to hyp-
oxia, thereby sustaining the contractile activity. This possibil-
ity is further supported by a study which showed that an IPC
stimulus applied to both legs prior to a 5 km running time trial
was able to prevent the decrease in brachial artery endothelial
function that would occur otherwise with strenuous lower ex-
tremity exercise, suggesting a remote effect of limb IPC in
preserving blood flow remotely during exercise [99]. Limb
IPC also appears to have an positive influence on the coronary
circulation during exercise through an increase in coronary
blood flow and a reduction in the coronary vascular resistance
[100, 101], though the exact mechanism for this change in
coronary flow is not known currently and its impact on the
exercise capacity may be somewhat limited However, consen-
sus on the positive effects of RIPC on exercise performance is
still lacking.
In fact, a recent study by Crisafulli et al. exploring the
effects of limb IPC on incremental exercise performance on
a cycle ergometer, exhibited no change in oxygen uptake,
stroke volume or cardiac output during exercise. However,
they noted an increase in maximal exercise performance after
limb IPC [102]. They postulated that the beneficial effect of
limb IPC could be related to an alteration in the perception of
fatigue. In our own study using healthy volunteers, we have
shown that the perception of pain/discomfort in relation to cuff
occlusion for RIPC reduces with subsequent cuff inflations
[28], possibly either due to some desensitisation of nerve sig-
nal at the site of occlusion with repeated exposure or due to
central alteration in pain perception. Although, it may be pos-
tulated that limb IPC may beneficially modify fatigue/pain
perception during subsequent exercise, the mechanisms and
whether or not they are systemic or locally mediated remains
to be elucidated.
Other studies showing beneficial effects of limb IPC on
exercise performance include a study by Bailey et al. which
showed that IPC (involving 5 min BP cuff inflation at
220 mmHg over both lower extremities) improved 5 km time
trial performance in healthy males and also reduced lactate
accumulation at sub-maximal level during an incremental
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running test [103]. The mechanism by which blood lactate
accumulation during exercise is attenuated via limb IPC is
unknown. Bailey et al. speculated that reduced ATP consump-
tion or increased efficiency of excitation-contraction coupling
during exercise caused by the preceding IPC, could have led
to the reduction in muscle lactate production. Interestingly, a
study in pigs has shown that IPC of skeletal muscles can
preserve the muscle ATP level at the end of lethal ischemia-
reperfusion as well as lower the accumulation of lactate, pro-
viding some support to this presumption [2].
Additional evidence that limb IPC has the potential to im-
prove maximal performance comes from Jean-St-Michel et al.
who found that limb IPC improved maximal performance in
national level swimmers [104]. They demonstrated that IPC
involving 4 cycles of upper limb ischemia for 5 min (induced
by BP cuff inflation to 15 mmHg above resting systolic BP)
each followed by 5 min of reperfusion, improved 100 m swim
time by an average of 0.7 s, which is of major competitive
significance over such a race distance [105]. This study sup-
ports the idea that limb IPC improves maximal performance
through remote actions, as the IPC stimulus was administered
only in one limb, but swimming itself involves several muscle
groups and all extremities. This is reinforced by the strong
clinical evidence that the benefits of RIPC are mediated by
both the systemic release of a humoral factor(s) as well as the
activation of neural pathways that can affect a number of
remote organ systems. In the latter study, authors speculated
that increased ATP productionmight contribute to the increase
in performance. There is certainly some evidence that IPC of
the myocardium can preserve ATP production during subse-
quent lethal ischemia via its effects on mitochondrial KATP
channels [106], but whether limb IPC has similar beneficial
effects on ATP production locally in skeletal muscles or re-
motely, remains to be shown. While some positive effects of
limb IPC seem possible in endurance activities and swim-
ming, it seems that IPC does not consistently improve
sprinting performance. In fact, recent work from Gibson
et al. showed that an IPC protocol of 3 cycles of 5 min occlu-
sion applied unilaterally (3×5 min on each leg) at 220 mmHg
had no effect on maximal sprints over 30 m [107]. Further-
more, IPC does not seem to improve performance during self-
paced 5 km running on an outdoor track or acutely affect
oxygen uptake and aerobic energy cost during the race
[108]. The post-race lactate levels were also unaffected by
limb IPC in this study conducted in well trained men [108].
These results are completely opposite to the findings of Bailey
et al. (2012) which showed an improvement in 5 km time trial
on a treadmill following an incremental test in healthy (but not
well trained) individuals [103], suggesting that maybe the
beneficial effects can only be evident in untrained populations
or perhaps that prior training can mimic the benefits of limb
IPC, such as by chronic limb ischemic preconditioning by
exercise induced hypoxia.
However, while maximal sprints may not benefit from IPC,
repeated sprints performed on a cycle ergometer seem to offer
a difference perspective. Patteron and coworkers recently
showed some marked beneficial effects of limb IPC (4×
5 min cuff inflation on both extremities at 220 mmHg follow-
ed by 5 min reperfusion) on repeated sprint cycling perfor-
mance as well as improvement in peak and mean power out-
put over the initial sprints [109]. The study also showed that
IPC maintained a better tissue saturation index during exer-
cise, compared to placebo, suggesting that improved oxygen
delivery to the muscles could be a contributing factor. Inter-
estingly, in this study there was no difference in fatigue per-
ception between IPC and placebo, although it should be noted
that subjects’warm up prior to exercise was carried out 30min
after IPC delivery which is in contrast to other studies where
warm up and exercise began soon after IPC. A clear area of
potential future investigation therefore relates to timing of IPC
delivery in further understanding its potential beneficial ef-
fects. Clearly more studies are needed to evaluate which as-
pect of sprint performance are positively influenced by limb
IPC as well as to develop a clearer understanding of the un-
derlying mechanisms.
It is known that group III and group IV afferent sensory
neurons respond to mechanical and metabolic alterations in
the skeletal muscles during exercise and initiate a reflex that is
transmitted to the cardiovascular regulation centers in the
brain stem, which in turn increases sympathetic efferent activ-
ity and reduces parasympathetic activity during exercise
[110]. This cause an increase in the heart rate and cardiac
output as well as vasoconstriction in non-active skeletal mus-
cle vascular beds to divert blood flow to the actively exercis-
ing skeletal muscles. This effect on the sympathetic and para-
sympathetic outflow during exercise is necessary to meet the
increase metabolic demands of the muscles being used active-
ly during exercise. It can be postulated that a similar reflex
pathway(s) may be activated by metabolic changes in the
skeletal muscles during limb IPC, which may have a benefi-
cial systemic and/or local effect during subsequent exercise or
that metabolic changes in the skeletal muscles during limb
IPCmay somehow positively influence these neural pathways
to improve exercise performance following IPC, through its
effect on blood flow locally or systemically. However, so far
the role of these neural reflexes in limb IPC has never been
evaluated. Intriguingly, it appears that limb IPC is able to at
least modulate local blood flow in the limb through increase in
functional sympatholysis, which is a term given to a reduction
in vasoconstriction that usually occurs during exercise due to
sympathetic activation. This effect of limb IPC may occur via
the activation of KATP channels in the vascular smooth mus-
cles locally and increased local production of nitric oxide due
to limb IPC [111]. It is important to recognize some key dif-
ferences in the various experimental protocols used for both
IPC and sham studies as well as the form of exercise used in
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these studies to investigate the effect of limb IPC as listed in
Table 3 [95, 99, 102–104, 107–109]. The majority of studies
have used either 220 mmHg or a fixed value (15 or 50mmHg)
above resting systolic BP. Based on the resting systolic pres-
sure, there may have been a wide difference in the cuff infla-
tion pressure used in these protocols. Similarly, while some
studies listed in Table 3 did not use a sham group, others used
a cuff inflation pressure ranging from 10 to 50 mmHg or
10 mmHg below resting diastolic blood pressure. Inflation
of a blood pressure cuff can affect the arteriovenous pressure
gradient and thereby limb perfusion [112, 113]. While this
effect may be negligible at very low pressures such as 10–
20 mmHg, the effect of slightly higher pressures such as
50 mmHg or 10 mmHg below the diastolic blood pressure is
unknown, and could potentially influence performance within
the sham group. The use of a low cuff inflation pressure in the
sham group also makes it difficult to adequately blind subjects
to their treatment, and could subconsciously influence the per-
formance of participants. Other variables in these studies in-
clude the inclusion or absence of a warm up period between
limb IPC and exercise, and the time interval between experi-
mental sessions (which ranged from 5–7 days to 7–14 days).
IPC and RIPC result in a “second window” of protection that
lasts 24–72 h [98, 114], but the time course of beneficial
effects of limb IPC in the exercise domain has not been
established. It seems reasonable to assume that improvements
to performance are unlikely to last beyond 1 week. The tested
exercise protocols themselves vary widely and involve differ-
ent muscle groups (running, swimming, cycling) and the
physiological changes in the body during these different forms
of exercise may also vary significantly, thereby having an im-
pact on the results. Finally, the subjects in these studies range
from “healthy individuals” to “well-trained athletes”, some of
whom compete at a national level. Although such individuals
are likely to vary markedly in their response to RIPC, these
differences have not yet been determined. It is important to take
such factors into account, not only in interpreting the results of
previous trials, but also in the design of future studies.
In conclusion, the effect of limb IPC in sports performance
is a relatively unexplored area of study and despite some ev-
idence suggesting its benefits in this domain, there is currently
insufficient experimental proof to draw confident conclusions
about its potential to acutely enhance performance with par-
ticular reference to elite athletes. The mechanisms underlying
this potential benefit are similarly very poorly understood and
under-investigated. Finally, it is unclear whether limb IPC can
add significant value over and above a well-planned warm-up,
particularly in well-trained, elite athletes [115–119]. In addi-
tion, application of limb IPC or RIPC may pose an ethical
dilemma regarding the appropriateness of its use to improve
exercise performance. This is particularly relevant now, as
controversies about the use of performance enhancing drugs
mar several sports.
Future Considerations
Clearly, there is need for further research, particularly with
regards to the mechanisms underlying the local and systemic
effects of limb IPC in order to clearly establish how and if they
can provide clinically significant cardioprotection in various
settings discussed above and/or improve exercise perfor-
mance. Currently there has been little more than speculation
about the mechanisms, and the possibility that limb IPC im-
proves performance via neural mechanisms has not been ex-
amined. Furthermore, it is unclear whether the upper or lower
limb is more effective in inducing the positive effects of limb
IPC/RIPC in terms of both potency as well as tolerability also
in the clinical setting. While tolerability and discomfort asso-
ciated with the limb IPC/RIPC protocol is not an issue in
anaesthetized subjects undergoing CABG, this could be an
important consideration for its wide spread utilization in
awake subjects, both patients and athletes. We have recently
shown that ischemia for RIPC can be more easily induced at
lower pressures in the upper limb and that RIPC is better
tolerated in the upper limb [28]. However, it is unclear wheth-
er the benefits of RIPC can be more effectively delivered
through IPC applied to the upper or lower limb or both. In
terms of RIPC delivery, there is currently no standardisation in
methodology such as duration of cuff inflation, number of
cycles/limbs(s) and the optimum cuff inflation pressure. It is
unclear, whether or not limb circumference and/or subcutane-
ous fat mass affect duration and pressure of inflation that
needs to be applied for RIPC. Clinical studies currently vary
markedly in the number of cycles of RIPC used [2–4], cuff
inflation pressure used for RIPC (200 mmHg vs. 15 mmHg
above resting systolic pressure vs. 40 mmHg above resting
systolic blood pressure), the number of limbs used for RIPC as
well as the choice of limbs (upper, lower or a combination of the
two) employed to deliver this cardioprotective intervention and
the timing of RIPC in relation to the CABG (Table 1). Studies in
the exercise domain have tended to use a higher cuff inflation
pressure (220 mmHg) compared with clinical studies, which
typically use 200 mmHg cuff inflation pressure for RIPC,
though the rationale for this is unclear. Furthermore, criteria to
aid practitioners in determining optimal dose–response are cur-
rently unknown. Clinical application of RIPC/limb IPC is also
made more difficult by a lack of information about the optimal
timingwhenRIPC should be delivered in relation to an ischemic
insult/reperfusion and there are numerous factors in a real world
scenario that can influence the delivery of this intervention in a
timely fashion. Absence of a unequivocally proven clinical bio-
marker that can confirm the adequacy of the RIPC stimulus,
considering the wide variation in protocols, as well as the opti-
mal timing of its delivery, prevent clinical translation of this
cardioprotective phenomenon. By analogywith direct IPC, there
may be expected to be a first window of protection lasting 1–2 h,
followed by a second window lasting 24–72 h [98, 114], but this
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remains to be investigated, to help define also the best timing for
this intervention to be applied. It is probable that the ideal pro-
tocol for RIPC and limb IPC as well as their timing will vary
based on the intended clinical/exercise setting for its application
and the desired effects. However, dose–response studies to de-
termine the optimal RIPC protocols for its different applications
and whether or not certain subjects (such as patients with diabe-
tes) respond in a different manner to a given RIPC stimulus than
others, do need to be performed to clarify this issue.
Conclusion
There is growing evidence that limb IPC is a promising non-
invasive tool for protecting the heart, through its remote effects
in the form of RIPC, and for improving some aspects of exercise
performance, through both its local and remote effects. Clinical
studies have so far been unable to show a consistent reduction in
myocardial injury/infarction or improvement in clinical out-
comes in the setting of coronary artery bypass grafting and
PCI performed for various indications. Recently concluded large
clinical trials, such as the ERICCA trial, that investigated the
effect of RIPC on clinical outcomes in the setting of CABGhave
disappointingly been neutral. This highlights that we are far
from widespread clinical application of this cardioprotective in-
tervention. Further large clinical trials exploring the effect of
RIPC on clinical outcomes in patients undergoing PCI are still
underway and will answer if the current protocols being used to
deliver this cardioprotective intervention can be beneficial in that
scenario. A clearer understanding of themechanisms underlying
RIPC, identification of the humoral factor responsible for the
transmission of the cardioprotective RIPC signal, investigation
of the optimal protocols to be used for RIPC/limb IPC as well as
delineating the time course of the effects are all needed to allow
for the translation of the benefits of this non-invasive interven-
tion into clinical practice as well as in the exercise domain.
Following further animal and clinical studies, RIPC/limb IPC
could potentially become a valuable technique both in clinical
practice and for its applications in the exercise domain.
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